Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Invion ( (AU:IVX) ) has issued an announcement.
Invion Limited has issued 7,250,269 fully paid ordinary shares at $0.14 per share as part of a Tranche 2 Placement. The company is in preliminary discussions with RMW Cho Group Limited to potentially expand the rights to Photosoft ™ technology to new territories or indications, although no binding agreement has been reached yet. This development could impact Invion’s market positioning and growth opportunities in the photodynamic therapy sector.
More about Invion
Invion is a life-science company focused on the global research and development of Photosoft ™ technology, which is used in the treatment of various cancers. The company holds licensing rights for this technology in Australia and New Zealand, with research and clinical trials funded by RMW Cho Group Limited. Invion is publicly listed on the Australian Securities Exchange (ASX: IVX).
Average Trading Volume: 84,473
Technical Sentiment Signal: Sell
Current Market Cap: A$6.2M
See more data about IVX stock on TipRanks’ Stock Analysis page.